Open AccessEffect of Telmisartan on the Regression of the Left Ventricular Hypertrophy in the Patients of Essential Hypertension
Author(s) -
Kumar Haraprasad Misra
Publication year - 2013
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2013/5416.3127
Subject(s) - atenolol , telmisartan , left ventricular hypertrophy , medicine , cardiology , essential hypertension , blood pressure , muscle hypertrophy
An increase in the Left Ventricular Mass as a result of muscle hypertrophy, has emerged as a powerful pressure independent risk factor for the cardiovascular mortality and morbidity. It is associated with a risk of death that is 3 times greater than the risk which is associated with hypertension alone. For the development of Left Ventricular Hypertrophy (LVH), in addition to a chronic increase in the pressure and/or volume overload, an elevation in the plasma ACE activity, plasma aldosterone levels, and the angiotensin-II concentrations play a major role .In this study, the effect of Telmisartan, a selective angiotension-II receptor blocker, was compared with that of Atenolol, a selective β1adrenergic receptor blocker, on the regression of LVH in the patients of essential hypertension.